An analysis of CA125 criteria in a cohort of patients studied in phase III randomized trial AURELIA in platinum-resistant ovarian cancer enabled us to conclude that cancer progression was detected earlier by imaging than by the CA125 rise [258]. This evidence concerns the gene MUC16 and ovarian cancer.